Factor Model (net +2.2)
Factor Model
net +2.2 4.7 / 10Leerink initiates TERN at Outperform, $4.8B leukemia drug upside
Watch: Watch for TERN-701 Phase 3 data and FDA interactions — that's the catalyst that either validates or blows up Leerink's $58 target. Hedge fund accumulation matters only if the drug works.
Leerink Partners just initiated coverage of Terns Pharmaceuticals on February 9 with an Outperform rating and $58 price target. The analyst sees a $4.8 billion peak revenue opportunity in TERN-701, the company's lead leukemia candidate, plus another $1.4 billion from second-line and beyond applications. Hedge fund momentum is building — the stock gained 42 hedge fund holders in Q4 2025 and ranks in the top 15 by hedge fund momentum.
A major biotech analyst putting a 6-figure price target on an unproven drug is a big signal, but execution risk is real. TERN-701 hasn't cleared late-stage trials yet, so the $4.8B thesis hinges entirely on Phase 3 success and regulatory approval. This is a binary bet on a single asset masquerading as an analyst call.
Our Trades
Full track record →Long Call · Insider Edge
TERN: earnings estimates raised 12%; insider buying detected; strong institutional convergence; IE rates bullish/medium.
2026-04-20
Long Call · Trail Blazer
2026-04-17
Evidence
5 older signals
Fundamentals & Data ▾
Recent transactions
Get alerted when TERN changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.